The opioid system in neurologic and psychiatric disorders and in their experimental models

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Evidence from experimental and clinical studies suggests the involvement of the endogenous opioid system in several neurologic and psychiatric disorders (Alzheimer's, Huntington's and Parkinson's diseases, drug-induced movement disorders, Gilles de la Tourette syndrome, stroke, ischemia, brain and spinal cord injury, epilepsy, schizophrenia and affective disorders). However, its involvement is rather a secondary one, perhaps being a severe consequence of a primary, nonopoid disturbance, Thus, treatment of an opioidergic manifestation of a disorder of nonopioidergic origin is necessarily symptomatic and targets only the restoration of the opioid system; such treatment may be beneficial in ameliorating the clinical symptoms of the disorder.

Original languageEnglish
Pages (from-to)395-428
Number of pages34
JournalPharmacology and Therapeutics
Volume46
Issue number3
DOIs
Publication statusPublished - 1990

Fingerprint

Nervous System Diseases
Opioid Analgesics
Psychiatry
Theoretical Models
Tourette Syndrome
Huntington Disease
Movement Disorders
Brain Ischemia
Mood Disorders
Spinal Cord Injuries
Parkinson Disease
Epilepsy
Schizophrenia
Alzheimer Disease
Stroke
Pharmaceutical Preparations
Clinical Studies

ASJC Scopus subject areas

  • Pharmacology

Cite this

The opioid system in neurologic and psychiatric disorders and in their experimental models. / Gulya, K.

In: Pharmacology and Therapeutics, Vol. 46, No. 3, 1990, p. 395-428.

Research output: Contribution to journalArticle

@article{95f73d8295214cd687a4a9c7835eebbf,
title = "The opioid system in neurologic and psychiatric disorders and in their experimental models",
abstract = "Evidence from experimental and clinical studies suggests the involvement of the endogenous opioid system in several neurologic and psychiatric disorders (Alzheimer's, Huntington's and Parkinson's diseases, drug-induced movement disorders, Gilles de la Tourette syndrome, stroke, ischemia, brain and spinal cord injury, epilepsy, schizophrenia and affective disorders). However, its involvement is rather a secondary one, perhaps being a severe consequence of a primary, nonopoid disturbance, Thus, treatment of an opioidergic manifestation of a disorder of nonopioidergic origin is necessarily symptomatic and targets only the restoration of the opioid system; such treatment may be beneficial in ameliorating the clinical symptoms of the disorder.",
author = "K. Gulya",
year = "1990",
doi = "10.1016/0163-7258(90)90026-X",
language = "English",
volume = "46",
pages = "395--428",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - The opioid system in neurologic and psychiatric disorders and in their experimental models

AU - Gulya, K.

PY - 1990

Y1 - 1990

N2 - Evidence from experimental and clinical studies suggests the involvement of the endogenous opioid system in several neurologic and psychiatric disorders (Alzheimer's, Huntington's and Parkinson's diseases, drug-induced movement disorders, Gilles de la Tourette syndrome, stroke, ischemia, brain and spinal cord injury, epilepsy, schizophrenia and affective disorders). However, its involvement is rather a secondary one, perhaps being a severe consequence of a primary, nonopoid disturbance, Thus, treatment of an opioidergic manifestation of a disorder of nonopioidergic origin is necessarily symptomatic and targets only the restoration of the opioid system; such treatment may be beneficial in ameliorating the clinical symptoms of the disorder.

AB - Evidence from experimental and clinical studies suggests the involvement of the endogenous opioid system in several neurologic and psychiatric disorders (Alzheimer's, Huntington's and Parkinson's diseases, drug-induced movement disorders, Gilles de la Tourette syndrome, stroke, ischemia, brain and spinal cord injury, epilepsy, schizophrenia and affective disorders). However, its involvement is rather a secondary one, perhaps being a severe consequence of a primary, nonopoid disturbance, Thus, treatment of an opioidergic manifestation of a disorder of nonopioidergic origin is necessarily symptomatic and targets only the restoration of the opioid system; such treatment may be beneficial in ameliorating the clinical symptoms of the disorder.

UR - http://www.scopus.com/inward/record.url?scp=0025272224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025272224&partnerID=8YFLogxK

U2 - 10.1016/0163-7258(90)90026-X

DO - 10.1016/0163-7258(90)90026-X

M3 - Article

C2 - 2188270

AN - SCOPUS:0025272224

VL - 46

SP - 395

EP - 428

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 3

ER -